Business Context and Reporting Period
This Form 8-K is a current report filed by CG Oncology, Inc. on November 10, 2025. The filing addresses Item 5.02 regarding the departure of a principal financial officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation for the new interim officer:
- Compensation Rate: $32,000 for the partial month of November 2025; $64,000 per month thereafter.
- Contract Term: Minimum of three months with an option to extend for an additional three months.
Material Changes
The primary material change reported is a leadership transition in the finance function:
- Resignation: Robert Lapetina resigned as interim principal financial and accounting officer, effective November 30, 2025.
- Appointment: Jim DeTore was appointed as the new interim principal financial and accounting officer, effective November 17, 2025.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of operational risks beyond the standard termination clauses of the new consulting agreement. The agreement allows for termination for material breach (with a 30-day cure period) or for any reason upon 60 days' prior written notice.
Investor Verification Checklist
- Verify the effective dates of the officer transition (Lapetina's departure on Nov 30 vs. DeTore's start on Nov 17).
- Confirm the total monthly cost of the new interim CFO arrangement ($64,000) against the company's current cash runway.
- Review the company's recent filings to understand the context of the previous interim CFO's departure.
- Monitor for any subsequent filings regarding the extension of the three-month consulting term.